Post-infection cough
Conditions
Interventions
Treatment group: ?Kumquat decoction
Control group:conventional treatment
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Presence of persistent cough during the convalescent phase of an acute upper respiratory tract infection, meeting the Western medicine diagnostic criteria for post-infectious cough (a) A clear history of respiratory tract infection at the onset, with acute catarrhal symptoms of a common cold such as rhinorrhea, sneezing, fever, headache, sore throat, or cough; (b) After the resolution of the acute catarrhal symptoms, the cough persists or even worsens, typically presenting as paroxysmal, irritating dry cough or with expectoration of a small amount of white mucoid phlegm, and the duration usually lasts for 3 to 8 weeks; (c) No abnormal rales detected upon lung auscultation; (d) Other causes of cough have been excluded. Age between 18 and 85 years (inclusive). The patient or their legal guardian has provided written informed consent.
Exclusion criteria
Exclusion criteria: Individuals with allergic constitution or those allergic to any components of the cough relief patch. Patients with chronic pulmonary diseases that may interfere with the assessment of cough symptoms, such as bronchiectasis, bronchopneumonia, chronic lung abscess, chronic cough lasting more than 8 weeks, chronic pharyngitis with cough, lung cancer, or bacterial respiratory infections. Heavy smokers (smoking index =400, calculated as pack-years smoked* or years smoked × cigarettes per day =400, e.g., smoking history =20 years and =20 cigarettes per day). Patients with severe underlying diseases or acute exacerbation of chronic conditions (e.g., acute heart failure), or those with acute cough caused by other critical illnesses such as acute myocardial infarction, left ventricular dysfunction, pulmonary embolism, or foreign body aspiration. Pregnant female subjects. Individuals with poor compliance who are unable to cooperate and complete the study. Participants who have been involved in another clinical trial within one month prior to this study or are currently participating in another clinical trial. Patients with incomplete data that would affect the judgment of efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to cough symptom resolution; | — |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of patients with resolved cough symptoms on day 3 and day 5 after treatment.;Change from baseline in Cough Evaluation Test (CET) score at day 3 and day 5 after treatment;Change from baseline in cough Numeric Rating Scale (NRS) score at day 3 and day 5 after treatment;Change from baseline in Leicester Cough Questionnaire (LCQ) score at day 3 and day 5 after treatment; | — |
Countries
China
Contacts
Public ContactZhongde Zhang
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed